Impact of P53 and SIRT1 in Type 2 Diabetes

DM Clinical Trial

Official title:

Investigating the Impact of p53 and SIRT1 in the Development of Type 2 DM Through the Treatment of Prediabetic Individuals by Either Nigetella Salivata or Metformin

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03925714
• Other study ID #: dm 2
• Status: Recruiting
• Phase: Phase 3
• Start date: April 1, 2019
• Est. completion date: December 2028

Study information

• Verified date: April 2019
• Source: Tanta University
• Contact: Sherief Abd-Elsalam, ass. prof.
• Phone: 00201147773440
• Email: sheriefabdelsalam[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Investigating the impact of p53 and SIRT1 in the development of type 2 DM

Description:

Investigating the impact of p53 and SIRT1 in the development of type 2 DM through the treatment of prediabetic individuals by either nigetella salivata or Metformin

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: December 2028
• Est. primary completion date: December 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Prediabetic subjects.

Exclusion Criteria:

• Confirmed diabetes.

• Hepatic or renal impairment.

Related Conditions & MeSH terms

• DM

Intervention

Other:
• life style
life sryle control only

Drug:
• Metformin
metformin twice daily
• Nigetella salivata
NS twice daily

Locations

Country	Name	City	State
Egypt	Sherief Abd-Elsalam	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Sherief Abd-Elsalam

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with improved insulin resistance	Number of patients showing improved insulin resistance	6 months